Market Cap 7.98M
Revenue (ttm) 0.00
Net Income (ttm) -34.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,500
Avg Vol 72,682
Day's Range N/A - N/A
Shares Out 950,000.00
Stochastic %K 0%
Beta 1.23
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastom...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 837 3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
Vedran1
Vedran1 Jul. 24 at 6:27 PM
$RNAZ Almost like in "old good days"... I am still confident though.
0 · Reply
Hovius
Hovius Jul. 24 at 3:08 PM
$RNAZ I still believe in this drug… nevertheless, took my mom to her oncologist this past week.. talked about their studies, which were conducted locally in Nashville... they both started phase one studies at approximately same time.. rnaz is starting phase two, while SC is actively in phase 3 trials.. I wonder why rnaz is so slow to progress..
0 · Reply
phantomtrader75
phantomtrader75 Jul. 24 at 1:56 PM
$RNAZ anyone know why this is selling off so badly the last few days?
3 · Reply
phantomtrader75
phantomtrader75 Jul. 24 at 1:32 PM
$RNAZ WTF
1 · Reply
Scrubinski
Scrubinski Jul. 23 at 8:58 PM
$RNAZ On the bright side, it can't drop $1.2 more than six more times.
1 · Reply
Scoty_D
Scoty_D Jul. 23 at 10:29 AM
$RNAZ Let's make it a good Thursday. Get the volume juices flowing.
0 · Reply
mbr60
mbr60 Jul. 22 at 6:45 PM
$RNAZ Something strange is going on… the stock is not moving. Looks like people finally understood the dilution 🤣
0 · Reply
GaryBx105
GaryBx105 Jul. 21 at 2:24 PM
$RNAZ assuming epic 100M share day pump, could pfd owners avoid 9.99% rule if they simultaneously converted and sold or even did it within 9.99% cap by converting and selling within 10 minute increments.
1 · Reply
mbr60
mbr60 Jul. 19 at 2:11 PM
$RNAZ Despite my frustration with TransCode and its poor treatment of shareholders, I want to be fair with the facts. The company has repeatedly made promises without clear execution. They previously said they had enough funding through 2026 and expected Phase 2 to begin in the first part of the year, yet we are now near the end of July with no clear meaningful progress. Now the focus seems to be on CK and the release/conversion of its shares. In my opinion, CK may be looking for liquidity or a way out. However, CK cannot sell 16 million shares all at once. Based on the ownership limit, any conversion would likely happen in stages around the 9.99% limit. The latest disclosure appears to show CK currently looking to convert/release only about 216,000 shares. So yes, dilution is a real risk, but the bigger concern is gradual dilution over time while the company continues delaying meaningful clinical updates.
1 · Reply
Hovius
Hovius Jul. 17 at 10:52 PM
$RNAZ dilution intensifies…
1 · Reply
Latest News on RNAZ
TransCode Therapeutics Transcript: AGM 2026

Jul 20, 2026, 9:30 AM EDT - 4 days ago

TransCode Therapeutics Transcript: AGM 2026


TransCode Therapeutics Proxy statement: Proxy filing

Jul 17, 2026, 8:00 AM EDT - 7 days ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Transcript: AGM 2026

Jul 2, 2026, 9:30 AM EDT - 22 days ago

TransCode Therapeutics Transcript: AGM 2026


TransCode Therapeutics Slides: Investor presentation

Jun 30, 2026, 7:00 AM EDT - 24 days ago

TransCode Therapeutics Slides: Investor presentation


TransCode Therapeutics Slides: Investor presentation

Jun 18, 2026, 7:00 AM EDT - 5 weeks ago

TransCode Therapeutics Slides: Investor presentation


TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Jun 8, 2026, 8:04 AM EDT - 6 weeks ago

TransCode Therapeutics to Host R&D Webcast on June 18, 2026


TransCode Therapeutics Proxy statement: Proxy filing

Jun 2, 2026, 8:00 AM EDT - 7 weeks ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 2 months ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

TransCode Therapeutics Quarterly report: Q1 2026


TransCode Therapeutics Proxy statement: Proxy filing

May 8, 2026, 8:00 AM EDT - 2 months ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Annual report: Q4 2025

Apr 15, 2026, 7:00 AM EDT - 3 months ago

TransCode Therapeutics Annual report: Q4 2025


TransCode Therapeutics Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Proxy statement: Proxy Filing

Mar 3, 2026, 7:00 AM EST - 5 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 7 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

TransCode Therapeutics Quarterly report: Q3 2025


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 9 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 10 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


Transcode Therapeutics Inc trading resumes

2025-10-08T13:45:31.000Z - 10 months ago

Transcode Therapeutics Inc trading resumes


Transcode Therapeutics to acquire Polynoma

2025-10-08T12:16:56.000Z - 10 months ago

Transcode Therapeutics to acquire Polynoma


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 10 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 10 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Transcript: AGM 2025

Aug 29, 2025, 9:30 AM EDT - 11 months ago

TransCode Therapeutics Transcript: AGM 2025


TransCode Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Quarterly report: Q2 2025


Transcode Therapeutics Inc trading resumes

2025-07-23T15:35:21.000Z - 1 year ago

Transcode Therapeutics Inc trading resumes


TransCode Therapeutics Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


Transcode Therapeutics Inc trading halted, news pending

2025-05-14T23:50:13.000Z - 1 year ago

Transcode Therapeutics Inc trading halted, news pending


TransCode Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

TransCode Therapeutics Quarterly report: Q1 2025


TransCode Therapeutics Transcript: AGM 2025

May 2, 2025, 9:30 AM EDT - 1 year ago

TransCode Therapeutics Transcript: AGM 2025


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Annual report: Q4 2024

Apr 17, 2025, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Annual report: Q4 2024


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 19, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

TransCode Therapeutics Quarterly report: Q3 2024


TransCode Therapeutics Proxy statement: Proxy Filing

Nov 13, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 28, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Jun 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Open Letter to Shareholders


TransCode Therapeutics Proxy statement: Proxy Filing

May 13, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Earnings release: Q4 2023

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Earnings release: Q4 2023


TransCode Therapeutics Annual report: Q4 2023

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Annual report: Q4 2023


TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split


Vedran1
Vedran1 Jul. 24 at 6:27 PM
$RNAZ Almost like in "old good days"... I am still confident though.
0 · Reply
Hovius
Hovius Jul. 24 at 3:08 PM
$RNAZ I still believe in this drug… nevertheless, took my mom to her oncologist this past week.. talked about their studies, which were conducted locally in Nashville... they both started phase one studies at approximately same time.. rnaz is starting phase two, while SC is actively in phase 3 trials.. I wonder why rnaz is so slow to progress..
0 · Reply
phantomtrader75
phantomtrader75 Jul. 24 at 1:56 PM
$RNAZ anyone know why this is selling off so badly the last few days?
3 · Reply
phantomtrader75
phantomtrader75 Jul. 24 at 1:32 PM
$RNAZ WTF
1 · Reply
Scrubinski
Scrubinski Jul. 23 at 8:58 PM
$RNAZ On the bright side, it can't drop $1.2 more than six more times.
1 · Reply
Scoty_D
Scoty_D Jul. 23 at 10:29 AM
$RNAZ Let's make it a good Thursday. Get the volume juices flowing.
0 · Reply
mbr60
mbr60 Jul. 22 at 6:45 PM
$RNAZ Something strange is going on… the stock is not moving. Looks like people finally understood the dilution 🤣
0 · Reply
GaryBx105
GaryBx105 Jul. 21 at 2:24 PM
$RNAZ assuming epic 100M share day pump, could pfd owners avoid 9.99% rule if they simultaneously converted and sold or even did it within 9.99% cap by converting and selling within 10 minute increments.
1 · Reply
mbr60
mbr60 Jul. 19 at 2:11 PM
$RNAZ Despite my frustration with TransCode and its poor treatment of shareholders, I want to be fair with the facts. The company has repeatedly made promises without clear execution. They previously said they had enough funding through 2026 and expected Phase 2 to begin in the first part of the year, yet we are now near the end of July with no clear meaningful progress. Now the focus seems to be on CK and the release/conversion of its shares. In my opinion, CK may be looking for liquidity or a way out. However, CK cannot sell 16 million shares all at once. Based on the ownership limit, any conversion would likely happen in stages around the 9.99% limit. The latest disclosure appears to show CK currently looking to convert/release only about 216,000 shares. So yes, dilution is a real risk, but the bigger concern is gradual dilution over time while the company continues delaying meaningful clinical updates.
1 · Reply
Hovius
Hovius Jul. 17 at 10:52 PM
$RNAZ dilution intensifies…
1 · Reply
focafoca99
focafoca99 Jul. 17 at 8:21 PM
$RNAZ amended its Series C Preferred Stock certificate to raise the ownership limit to 9.99%.
1 · Reply
Vedran1
Vedran1 Jul. 14 at 3:38 PM
$RNAZ Considering adding around here.
2 · Reply
mbr60
mbr60 Jul. 10 at 9:27 PM
$RNAZ First, welcome to the new victims who are joining us on a journey that has not truly started for almost a year. I want to be clear: I am one of the old victims of this stock. I have been stuck here for almost a year and a half, and during that time this company has gone through multiple reverse splits. Now the company has raised financing from several large investors, including CK. At first, I was surprised that CK agreed to this deal. But now, before even completing one full year, it looks like CK may want liquidity or a way out of this company. Here is the reality as I see it: on July 20, shareholders are expected to vote on releasing/converting CK-related shares, along with other preferred shares, which could bring the share count close to around 16 million shares. If that happens, the stock could easily fall below $1.X again, and then we may face another reverse split. Welcome to this black hole.👎
1 · Reply
Vedran1
Vedran1 Jul. 10 at 2:26 PM
$RNAZ June 18th Webinar, Tom Fitzgerald-CFO: "...here's a summary of our capital position right now. This is using the share price of a few days ago, 5.69 a share. Prior to any of the convertibility that I described with the series A, B, and C shares and the Yorkville shares, we've got about 950,000 shares outstanding, giving us a market cap of 5 million, just over 5 million dollars, which we think doesn't fully reflect the the company's potential or accomplishments to this point, on a proforma of basis assuming conversion of all the shares that I've talked about we'll have about 18.6 million shares of outstanding and that would give us a proforma market cap of a little bit over 100 million dollars. ..." Continued bellow
1 · Reply
Zardiw
Zardiw Jul. 10 at 1:04 PM
Early alert paid off: $GMM up 163%. Previous winners: $VRAX $RYOJ $RNAZ Don't miss the next: https://DDAmanda.com/#pricing
1 · Reply
GaryBx105
GaryBx105 Jul. 10 at 12:09 PM
$RNAZ while pfd conversion was approved july 2, company needed nasd approval for initial listing before convesion can be voted on. so it allowed time to get nasd approval, followed by another shareholder vote on pfd conversion on am of july 20.
0 · Reply
johnrivers0110
johnrivers0110 Jul. 10 at 12:03 AM
$RNAZ $TDTH $FBRX 🔺Thank you for your sacrifice into $JLHL The FiB 🔺
0 · Reply
Zardiw
Zardiw Jul. 10 at 12:02 AM
Early alert paid off: $JLHL up 318%. Similar early alerts: $RNAZ $TDTH $FBRX Find the next one: https://DDAmanda.com/#pricing
0 · Reply
kunnskap
kunnskap Jul. 9 at 8:58 PM
$RNAZ They want to convert company’s Series A and Series B Non-Voting Convertible Preferred Stock into common stock. Gemini AI says : A company typically converts its Series A and Series B Non-Voting Convertible Preferred Stock into common stock to simplify its capital structure and eliminate complex, senior liquidation preferences. This conversion is most frequently triggered by an Initial Public Offering (IPO), a major acquisition, or to prepare for a new venture capital funding round. [1, 2, 3, 4] Here are the primary drivers for this conversion: * Preparing for an IPO or Acquisition * Eliminating Liquidation Preferences * Removing Burdensome Dividend Obligations * Simplifying Corporate Governance * Mandatory Conversion Thresholds
0 · Reply
kunnskap
kunnskap Jul. 9 at 8:47 PM
$RNAZ Market Cap insanlely low when TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by Unleash to the Unleash drug candidates together with the acquisition of all rights to the drug candidates owned by Unleash.
0 · Reply
RotterdamTrade
RotterdamTrade Jul. 9 at 8:45 PM
$RNAZ can we sell tomorrow above 10 ?
0 · Reply
Itinerant
Itinerant Jul. 9 at 5:29 PM
$RNAZ Maybe the market is beginning to understand what this company has to offer. We will see.
1 · Reply